BlackRock’s Verve Therapeutics VERV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$82.6M Sell
7,356,721
-521,515
-7% -$5.86M ﹤0.01% 2144
2025
Q1
$36M Buy
7,878,236
+352,766
+5% +$1.61M ﹤0.01% 2538
2024
Q4
$42.4M Buy
7,525,470
+249,123
+3% +$1.41M ﹤0.01% 2521
2024
Q3
$35.2M Buy
7,276,347
+656,343
+10% +$3.18M ﹤0.01% 2648
2024
Q2
$32.3M Buy
6,620,004
+1,246,827
+23% +$6.08M ﹤0.01% 2660
2024
Q1
$71.4M Buy
5,373,177
+937,696
+21% +$12.5M ﹤0.01% 2217
2023
Q4
$61.8M Buy
4,435,481
+437,082
+11% +$6.09M ﹤0.01% 2308
2023
Q3
$53M Buy
3,998,399
+151,696
+4% +$2.01M ﹤0.01% 2339
2023
Q2
$72.1M Buy
3,846,703
+300,218
+8% +$5.63M ﹤0.01% 2236
2023
Q1
$51.1M Sell
3,546,485
-47,589
-1% -$686K ﹤0.01% 2392
2022
Q4
$69.5M Buy
3,594,074
+217,864
+6% +$4.22M ﹤0.01% 2223
2022
Q3
$116M Buy
3,376,210
+792,139
+31% +$27.2M ﹤0.01% 1854
2022
Q2
$39.5M Buy
2,584,071
+425,509
+20% +$6.5M ﹤0.01% 2608
2022
Q1
$49.3M Buy
2,158,562
+915,090
+74% +$20.9M ﹤0.01% 2558
2021
Q4
$45.8M Buy
1,243,472
+299,015
+32% +$11M ﹤0.01% 2673
2021
Q3
$44.4M Buy
944,457
+414,533
+78% +$19.5M ﹤0.01% 2712
2021
Q2
$31.9M Buy
+529,924
New +$31.9M ﹤0.01% 2963